Blow For Celgene As Revlimid Trial Miss Removes Blockbuster Indication
Celgene Corp.'s hopes of extending the market reach of its blockbuster oncology therapy Revlimid (lenalidomide) have taken a blow as Phase III data for the drug in elderly diffuse large B-cell lymphoma (DLBCL) patients have failed to show benefit on overall survival.
You may also be interested in...
Celgene will pay $9bn to buy the 90.3% of Juno that it doesn't already own, seeking to not only become a leader in the CAR-T field, but to increase its leadership in non-Hodgkin lymphoma, multiple myeloma, other hematological malignancies.
A run of bad luck for developers of potential treatments for diffuse large B-cell lymphoma – Roche, Celgene and Novartis – has withered the late-stage pipeline for an indication that has long been in need of new therapies. Scrip and Datamonitor Healthcare take a look at what's next for the disease.
Sales of the psoriasis drug increased 170% in the second quarter to $242m, giving the blood cancer specialist a strong anchor as it looks to expand in inflammation and immunology.